Medical Articles 9/27

Posted by rob on September 27, 2007 under Uncategorized | Be the First to Comment

Apoptotic pathway induced by noscapine in human myelogenous leukemic cells.

HLA Class II Allele and Haplotype Frequencies in Iranian Patients with Leukemia.

Correction of Celiac Disease After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia.

Medical Articles 9/25

Posted by rob on September 25, 2007 under Uncategorized | Be the First to Comment

New drugs in thyroid cancer.

Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia.
Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma.
Absolute
lymphocyte count on day 30 is a surrogate for robust hematopoietic
recovery and strongly predicts outcome after T cell-depleted allogeneic
stem cell transplantation.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation.
[Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives bearing dithiocarbamate chains]
The history of myeloproliferative disorders: before and after Dameshek.

Classification
and diagnosis of myeloproliferative neoplasms: The 2008 World Health
Organization criteria and point-of-care diagnostic algorithms.

Rainbow Hamster

Posted by rob on September 24, 2007 under Uncategorized | Be the First to Comment


From heatherlynchriza

Medical Articles 9/20

Posted by rob on September 20, 2007 under Uncategorized | Be the First to Comment

Sustained
remissions and low rate of BCR-ABL resistance mutations with imatinib
treatment chronic myelogenous leukemia in patients treated in late
chronic phase: A 5-year follow up.

Reactive
oxygen species, DNA damage, and error-prone repair: a model for genomic
instability with progression in myeloid leukemia?
The
Role of Platelet/Endothelial Cell Adhesion Molecule 1 (CD31) and CD38
Antigens in Marrow Microenvironmental Retention of Acute Myelogenous
Leukemia Cells.
CAG
regimen enables relapsed or refractory T-cell acute lymphocytic
leukemia patients to achieve complete remission: A report of six cases.
[Benefits of mycophenolate mofetil for refractory graft-versus-host disease]
[Transient
chromosomal abnormalities following autologous peripheral blood stem
cell transplantation for acute myelogenous leukemia]
t(5;12)(q13;p13) in acute myeloid leukemia with preceding granulocytic sarcoma.

Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22)(q23;q11.2).

Medical Articles 9/14

Posted by rob on September 15, 2007 under Uncategorized | Be the First to Comment

Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy.

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Phase
1 study of tipifarnib in combination with imatinib for patients with
chronic myelogenous leukemia in chronic phase after imatinib failure.
Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.
Utilization
of recombinant activated factor VII for intracranial hematoma
evacuation in coagulopathic nonhemophilic neurosurgical patients with
normal international normalized ratios.
Studies in target-based treatment.
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

The future is now for the treatment of chronic myelogenous leukemia.

Medical Articles 9/8

Posted by rob on September 9, 2007 under Uncategorized | Be the First to Comment

AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies.

Neutrophilic
eccrine hidradenitis with sclerodermoid change heralding the relapse of
acute myelogenous leukemia: is this a paraneoplastic phenomenon?
A
double-blind trial on prophylactic voriconazole (VRC) or placebo during
induction chemotherapy for acute myelogenous leukaemia (AML).
Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358.

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Medical Articles 9/6

Posted by rob on September 7, 2007 under Uncategorized | Be the First to Comment

Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies.

Simultaneous
regression of Philadelphia chromosome and multiple nonrecurrent clonal
chromosomal abnormalities with imatinib mesylate in a patient
autografted 22 years before for chronic myelogenous leukemia.

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.

Medical Articles 9/5

Posted by rob on September 5, 2007 under Uncategorized | Be the First to Comment

Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

Leukemia, an effective model for chemical biology and target therapy.

[Eight years using the "Mexican method" for allogeneic hematopoietic stem cell transplants]

home top